My point was all the IsoPet progress and possible applications to human cancer treatments is utterly moot if RDGL never makes it to human trials, and the past two years of mismanagement, lost most of 2021, then resisting FDA advice, etc., doesn't inspire confidence that RDGL can get that job done. As far as pps increase upon IDE submission, very hard to say now because because of the massive dilution we're facing if RDGL has to do next offering before IDE submission, which by the day looks more and more likely. RDGL's plan B of IsoPet generating millions of $ by this point didn't pan out, so the only remaining card to get decent valuation for the up coming offering is IDE submission beforehand and, again, that no longer appears to be in the cards.
In business, time is always of the essence. Sure wish MK had understood that after the $4 million raise into BDD speculation and focused on IDE application then. Here we are about two years later still waiting on RDGL to submit IDE application. All the delays have been on RDGL.
Market Data 
Markets 
AI
